Zobrazeno 1 - 10
of 225
pro vyhledávání: '"William C. Zamboni"'
Autor:
Lauren S.L. Price, Judith N. Rivera, Andrew J. Madden, Leah B. Herity, Joseph A. Piscitelli, Savannah Mageau, Charlene M. Santos, Jose R. Roques, Bentley Midkiff, Nana N. Feinberg, David Darr, Sha X. Chang, William C. Zamboni
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Minibeam radiation therapy is an experimental radiation therapy utilizing an array of parallel submillimeter planar X-ray beams. In preclinical studies, minibeam radiation therapy has been shown to eradicate tumors and cause significantly
Externí odkaz:
https://doaj.org/article/740570a053e546c4b20b6d47a8927c6a
Publikováno v:
Antibodies, Vol 10, Iss 3, p 30 (2021)
Antibody-drug conjugates (ADCs) appear to be in a developmental boom, with five FDA approvals in the last two years and a projected market value of over $4 billion by 2024. Major advancements in the engineering of these novel cytotoxic drug carriers
Externí odkaz:
https://doaj.org/article/86bf972f21754c5aacaf27bbb3da639c
Publikováno v:
Pharmaceutics, Vol 13, Iss 1, p 114 (2021)
Major developments in nanomedicines, such as nanoparticles (NPs), nanosomes, and conjugates, have revolutionized drug delivery capabilities over the past four decades. Although nanocarrier agents provide numerous advantages (e.g., greater solubility
Externí odkaz:
https://doaj.org/article/2baed0c966ee4478b580c87ac524e198
Autor:
Andrew T. Lucas, Ryan Robinson, Allison N. Schorzman, Joseph A. Piscitelli, Juan F. Razo, William C. Zamboni
Publikováno v:
Antibodies, Vol 8, Iss 1, p 3 (2019)
The rapid advancement in the development of therapeutic proteins, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), has created a novel mechanism to selectively deliver highly potent cytotoxic agents in the treatment of canc
Externí odkaz:
https://doaj.org/article/9a6f5e6f80ac4da8837653e210995036
Autor:
Andrew T. Lucas, Lauren S. L. Price, Allison N. Schorzman, Mallory Storrie, Joseph A. Piscitelli, Juan Razo, William C. Zamboni
Publikováno v:
Antibodies, Vol 7, Iss 1, p 10 (2018)
Major advances in therapeutic proteins, including antibody–drug conjugates (ADCs), have created revolutionary drug delivery systems in cancer over the past decade. While these immunoconjugate agents provide several advantages compared to their smal
Externí odkaz:
https://doaj.org/article/7d650a79f5314a98a635b976f287e44e
Autor:
Ardavan Akhavan, Kevin H. McHugh, Georgi Guruli, Robert R. Bies, William C. Zamboni, Sandra Strychor, Joel B. Nelson, Beth R. Pflug
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 8, Iss 9, Pp 725-732 (2006)
Endothelin (ET) 1 is important in the growth of prostate cancer cells through the activation of the endothelin A (ETA) receptor. ET receptor blockade is a new therapeutic target in treating advanced prostate cancer. This study investigates the impact
Externí odkaz:
https://doaj.org/article/a3b312acbe45456f84b5e624e976e455
Autor:
Norman E. Sharpless, Charles M. Perou, Gary L. Johnson, William C. Zamboni, Jian Jin, Austin J. Combest, Soren M. Johnson, James S. Duncan, Martin C. Whittle, Adam D. Pfefferle, Patrick M. Dillon, David B. Darr, Jerry E. Usary, Patrick J. Roberts
PDF file, 53K, MP1U Dosing Regimens.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06aab9f024e8516676b9d1a778432315
https://doi.org/10.1158/1078-0432.22455326.v1
https://doi.org/10.1158/1078-0432.22455326.v1
Autor:
William C. Zamboni, Charles M. Perou, Andrew C. Dudley, Arlin B. Rogers, Teresa K. Tarrant, C. Ryan Miller, Nana Nikolaishvili-Feinberg, Stephanie Cohen, Bentley R. Midkiff, Jamie L. Jordan, Alain Valdivia, Mark Ross, Charlene M. Santos, David B. Darr, Gina Song
Supplementary Fig. S3. Profiling of collagen in basal-like C3-TAg model and claudin-low T11 model at baseline and at 96 h after administration of PLD or NL-doxo at 6 mg/kg I.V. x 1 via tail vein
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc71154b91cc2042f3442bd51e4b8470
https://doi.org/10.1158/1078-0432.22456287.v1
https://doi.org/10.1158/1078-0432.22456287.v1
Autor:
William C. Zamboni, Charles M. Perou, Andrew C. Dudley, Arlin B. Rogers, Teresa K. Tarrant, C. Ryan Miller, Nana Nikolaishvili-Feinberg, Stephanie Cohen, Bentley R. Midkiff, Jamie L. Jordan, Alain Valdivia, Mark Ross, Charlene M. Santos, David B. Darr, Gina Song
Supplementary Data. Table S1. Product information from FormuMax Scientific, Inc. Table S2. Doxorubicin AUC0-96h in plasma, tissues, and tumor in the C3-TAg model and the T11 model after PLD or NL-doxo administration at 6 mg/kg I.V. x 1 via tail vein
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d5eef07a6263cca0d09627ab18668a7
https://doi.org/10.1158/1078-0432.22456296.v1
https://doi.org/10.1158/1078-0432.22456296.v1
Autor:
William C. Zamboni, Charles M. Perou, Andrew C. Dudley, Arlin B. Rogers, Teresa K. Tarrant, C. Ryan Miller, Nana Nikolaishvili-Feinberg, Stephanie Cohen, Bentley R. Midkiff, Jamie L. Jordan, Alain Valdivia, Mark Ross, Charlene M. Santos, David B. Darr, Gina Song
Purpose: Tumor cells are surrounded by a complex microenvironment. The purpose of our study was to evaluate the role of heterogeneity of the tumor microenvironment in the variability of nanoparticle (NP) delivery and efficacy.Experimental Designs:C3(
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccbc13d16ad8b3f6c8192576b91d968a
https://doi.org/10.1158/1078-0432.c.6523266.v1
https://doi.org/10.1158/1078-0432.c.6523266.v1